Albumin replacement therapy targeting serum levels ≥ 3.0 g/dL does not improve 90-day survival in patients with septic shock in the emergency department, a trial shows.

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid ...

Tirzepatide, which is marketed as Zepbound for chronic weight management, is a dual GIP and GLP-1 receptor agonist that has ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

A once-daily pill called sulthiame cut breathing interruptions during sleep by up to 47 percent in adults with obstructive sleep apnea, according to a completed phase 2 clinical trial conducted across ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that tecovirimat did not improve clinical outcomes for adults with clade II mpox ...

High-dose Vitamin D doesn't reduce acute COVID severity but shows a promising signal for reducing Long COVID and brain fog.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.